Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and dactolisib

quinazolines has been researched along with dactolisib in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's10 (76.92)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Baselga, J; Beijersbergen, RL; Bernards, R; Eichhorn, PJ; Gili, M; Guzman, M; Nijkamp, W; Scaltriti, M; Seoane, J; Serra, V; Valero, V1
Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY1
Ahuja, D; Amin, DN; Blair, JA; Hann, B; Koch, KM; McMahon, M; Moasser, MM; Sergina, N; Shokat, KM; Wang, D1
Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S1
Buck, JR; Cheung, YY; Coffey, RJ; Dawson, ES; Hight, MR; Manning, HC; Nickels, ML; Saleh, S; Tang, D; Washington, MK; Zhao, P1
Axelrod, MJ; Conaway, MR; Gioeli, DG; Gordon, V; Jameson, MJ; Leimgruber, SS; Mendez, RE; Sharlow, ER; Weber, MJ1
Brady, SW; Chang, CC; Chang, J; Ellis, K; Esteva, FJ; Landis, MD; Muller, WJ; Priya, P; Sahin, O; Wang, H; Wang, Q; Wong, ST; Yu, D; Zhang, Q; Zhu, R1
Li, H; Ma, D; Qu, Y; Wu, X; Yang, Y; Yin, Y1
Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H1
Airhart, S; Bult, C; Davis, RR; de Vere White, RW; Gandara, DR; Ghosh, PM; Gill, P; Keck, J; Lin, TY; Liu, E; Pan, CX; Tepper, CG; Zhang, H1
Amin, DN; Gulizia, N; Moasser, MM; Ruiz-Saenz, A1
Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU1
Akudugu, JM; Hamid, MB; Serafin, AM1

Trials

1 trial(s) available for quinazolines and dactolisib

ArticleYear
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Animals; Female; Heterografts; Humans; Imidazoles; Lapatinib; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2015

Other Studies

12 other study(ies) available for quinazolines and dactolisib

ArticleYear
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
    Cancer research, 2008, Nov-15, Volume: 68, Issue:22

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carrier Proteins; Cell Line, Tumor; Drug Resistance; Female; Humans; Imidazoles; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab

2008
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Nov-17, Volume: 106, Issue:46

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2009
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
    Science translational medicine, 2010, Jan-27, Volume: 2, Issue:16

    Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lapatinib; Mice; Mitogen-Activated Protein Kinases; Neoplasms; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction

2010
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
    International journal of cancer, 2013, Jul-15, Volume: 133, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome

2013
A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Apr-15, Volume: 20, Issue:8

    Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorobenzenes; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; Indoles; Mice, Inbred C57BL; Mice, Nude; Organophosphates; Peptides; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Quinolines; Radiopharmaceuticals; Sulfonamides; Tissue Distribution; Xenograft Model Antitumor Assays

2014
p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.
    Cellular signalling, 2014, Volume: 26, Issue:8

    Topics: Apoptosis; Cell Line, Tumor; ErbB Receptors; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases

2014
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
    Cell research, 2014, Volume: 24, Issue:5

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Lapatinib; Mice; Mice, Transgenic; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Tumor Cells, Cultured

2014
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Journal of experimental & clinical cancer research : CR, 2014, Jun-17, Volume: 33

    Topics: Animals; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gefitinib; Humans; Imidazoles; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays

2014
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
    Cancer research, 2015, May-15, Volume: 75, Issue:10

    Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured

2015
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
    Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Indoles; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2015
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC cancer, 2017, Nov-03, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2017
Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.
    European journal of pharmacology, 2021, Dec-05, Volume: 912

    Topics: Aniline Compounds; Breast Neoplasms; Cell Line; Cell Survival; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Quinolines; Radiation Tolerance; Sulfonamides; TOR Serine-Threonine Kinases; Tyrphostins; Uterine Cervical Neoplasms; X-Rays

2021